Enzo Biochem, Inc.
ENZ
$1.09
-$0.02-1.80%
| 01/31/2024 | 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 13.83% | 9.90% | 100.62% | -38.57% | -77.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.83% | 9.90% | 100.62% | -38.57% | -77.93% |
| Cost of Revenue | -6.22% | -5.19% | 86.05% | -9.84% | -74.12% |
| Gross Profit | 45.76% | 37.43% | 118.66% | -83.90% | -82.12% |
| SG&A Expenses | -7.74% | 25.42% | 125.03% | 33.94% | -57.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.95% | 13.21% | 100.59% | 8.15% | -63.86% |
| Operating Income | 51.93% | -18.30% | 100.77% | -398.88% | -771.34% |
| Income Before Tax | 70.16% | -6.00% | 84.87% | -212.88% | -8.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 70.16% | -6.00% | 84.87% | -212.88% | -8.93% |
| Earnings from Discontinued Operations | 73.92% | 82.18% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 72.96% | 37.79% | 781.02% | -212.88% | -326.37% |
| EBIT | 51.93% | -18.30% | 100.77% | -398.88% | -771.34% |
| EBITDA | 51.06% | -36.03% | 106.92% | -523.84% | -383.57% |
| EPS Basic | 73.91% | 39.62% | 775.66% | -208.73% | -323.91% |
| Normalized Basic EPS | 71.16% | -2.91% | 86.64% | -261.96% | -5,200.00% |
| EPS Diluted | 73.91% | 39.65% | 769.68% | -208.73% | -323.91% |
| Normalized Diluted EPS | 71.16% | -2.91% | 86.64% | -261.96% | -5,200.00% |
| Average Basic Shares Outstanding | 3.61% | 3.00% | 1.16% | 1.38% | 0.53% |
| Average Diluted Shares Outstanding | 3.61% | 3.00% | 1.16% | 1.38% | 0.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
